A Split-Face Study Assessing the Clinical Benefit, Tolerability and Subject Satisfaction of a Dermocosmetic in Subjects with Rosacea Associated with Erythema and Sensitive Skin.

Conclusion: Study results concerning M89 are encouraging for its use either alone or as an adjuvant daily skin care to topical medication in patients with persistent centrofacial erythema of rosacea with no more than 3 papules and pustules. PMID: 33116738 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/33116738?dopt=Abstract

Source: Clinical, Cosmetic and Investigational Dermatology - October 30, 2020 Category: Dermatology Tags: Clin Cosmet Investig Dermatol Source Type: research